Who owns Tempalgin?
Tempalgin is owned by Sopharma (Bulgaria, BSE Sofia: SFA).[1]
This ownership is reported in official statements but has not yet been matched to a regulatory filing.
Evidence: Sopharma Group consolidated management report for the first half of 2026, Sopharma AD, 30 June 2026. Last checked .
Key facts
- Current owner
- Sopharma AD reported
- Owner HQ
- 🇧🇬 Bulgaria, Sofia
- Origin
- 🇧🇬 Bulgaria
- Category
- Consumer health › Over-the-counter medicine › Pain relief
- Parent ticker
- BSE Sofia: SFA WSE: SPH
- Last verified
- · 1 sources
About Tempalgin
Tempalgin is Sopharma's combination painkiller, a film-coated tablet of 500 mg metamizole with 20 mg triacetonamine 4-toluenesulfonate, and the company lists it among the six brands it calls its leading strategic products in consumer healthcare. Its Albanian authorisation was renewed in the first half of 2026 and a Belarusian registration was submitted in the same period, while a reformulated tablet is among the thirty-three products in pharmaceutical development.
Ownership timeline of Tempalgin
Where Tempalgin sits in Sopharma
Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.
Open the full Sopharma ownership tree →
See the full Sopharma brand portfolio (6) →
Other brands owned by Sopharma
Sopharma controls 6 brands on Brandtree, 6 of them in consumer health.
Also in consumer health
Other brands in pain relief, and who owns them
The 37 brands in pain relief on Brandtree belong to 21 owners. The largest is Haleon, with 3; Sopharma has 2.
| Brand | Owner | Owner based in |
|---|---|---|
| Advil | Haleon | 🇬🇧 United Kingdom |
| Air Salonpas | Hisamitsu Pharmaceutical | 🇯🇵 Japan |
| Motrin | Kenvue | 🇺🇸 United States |
| Dafalgan | Taisho Pharmaceutical | 🇯🇵 Japan |
| Nicotex | Cipla | 🇮🇳 India |
| Mentho Plus | Emami | 🇮🇳 India |
| Bufferin (United States) | Genomma Lab | 🇲🇽 Mexico |
| Doril | Hypera | 🇧🇷 Brazil |
About the owner: Sopharma
Sopharma is a publicly listed company headquartered in Sofia, Bulgaria, founded in 1933. Brandtree records 6 brands under its control, and it is listed as BSE Sofia: SFA and WSE: SPH.
Sopharma is the largest Bulgarian pharmaceutical company, a producer, exporter and domestic distributor of prescription medicines, generics, herbal-based substances, food supplements, cosmetics and medical devices. It was established in 1933, when the Bulgarian Pharmacists' Cooperative Society built the first laboratory for manufacturing medicines in the country on the edge of Sofia, and it became a private company in 2000. The group manufactures at twenty specialised facilities across seven sites in Bulgaria, Serbia and Ukraine, and distributes through Sopharma Trading, which it owns 87.32 per cent of, and through subsidiaries in Russia, Ukraine, Kazakhstan, Poland and Belarus.
🇧🇬 Tempalgin and other Bulgarian brands
Brandtree records a controlling owner for 20 brands that began in Bulgaria. 13 of them (65%) are now controlled by a company headquartered in another country; Tempalgin is not one of them.
- A1 Bulgaria — América Móvil 🇲🇽
- Angel's Estate — Maspex 🇵🇱
- Bulgaria Air — Bulgarian Airways Group 🇧🇬
- DSK Bank — OTP Bank 🇭🇺
- Devin — Spadel 🇧🇪
- Gorna Bania — Multi Group 🇦🇲
Frequently asked questions
Who is the parent company of Tempalgin?
The parent company of Tempalgin is Sopharma, a publicly listed company headquartered in Bulgaria.
Is Tempalgin Bulgarian?
Yes. Tempalgin originated in Bulgaria and its owner, Sopharma, is also headquartered in Bulgaria.
Is Tempalgin still owned by Sopharma?
Yes. As of 20 September 2026, Tempalgin is still owned by Sopharma. The ownership record was last checked against primary sources on that date.
Sources (1) & corrections
Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.
- [1] Sopharma Group consolidated management report for the first half of 2026 — Sopharma AD, Stock exchange filing, published 30 June 2026; retrieved 20 September 2026.
Report a correction Opens a pre-filled GitHub issue. See our corrections policy.